Works matching AU Andreeff, M.

Results: 64

Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.

Published in:

2012

By:

Mak DH;
Wang RY;
Schober WD;
Konopleva M;
Cortes J;
Kantarjian H;
Andreeff M;
Carter BZ;
Mak, D H;
Wang, R-Y;
Schober, W D;
Konopleva, M;
Cortes, J;
Kantarjian, H;
Andreeff, M;
Carter, B Z

Publication type:

journal article

Untersuchungen zum Einfluß von Korrekturverfahren auf die Volumenquantifizierung in SPECT-Daten.

Published in:

Biomedical Engineering / Biomedizinische Technik, 1998, v. 43, p. 470

By:

Foe Owono, G. D.;
Schmitt, T.;
Oehme, L.;
Andreeff, M.;
Franke, W. G.;
Freyer, R.

Publication type:

Article

Equipmcnt zur Modifikation der Nuklearmedizinischen Lungen- diagnostik als getriggerte SPECT - Darstellung, Phantomstudien und klinische Nutzung.

Published in:

Biomedical Engineering / Biomedizinische Technik, 1998, v. 43, p. 76

By:

Andreeff, M.;
Kropp, J.;
Beuthien-Baumann, B.;
Oehme, L.;
Hliscs, R.;
Schellong, S.;
Prescher, Y.;
Franke, W.-G.;
Daniel, W.-G.

Publication type:

Article

3D-Segmentierungsverfahren zur Volumenquantifizierung in ECT-Daten.

Published in:

Biomedical Engineering / Biomedizinische Technik, 1998, v. 43, p. 70

By:

Schmitt, T.;
Oehme, L.;
Andreeff, M.;
Foe Owono, G. D.;
Franke, W.-G.;
Freyer, R.

Publication type:

Article

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.

Published in:

2011

By:

Jin, L.;
Tabe, Y.;
Kimura, S.;
Zhou, Y.;
Kuroda, J.;
Asou, H.;
Inaba, T.;
Konopleva, M.;
Andreeff, M.;
Miida, T.

Publication type:

journal article

Treatment of Myelodysplastic Syndromes with AML-Type Chemotherapy.

Published in:

Leukemia & Lymphoma, 1993, v. 11, n. S2, p. 59, doi. 10.3109/10428199309064263

By:

Estey, E.;
Pierce, S.;
Kantarjian, H.;
O'brien, S.;
Beran, M.;
Andreeff, M.;
Escudier, S.;
Koller, C.;
Kornblau, S.;
Robertson, L.;
Keating, M.

Publication type:

Article

P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT‐NAIVE AND RELAPSED HIGH‐RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA.

Published in:

HemaSphere, 2022, v. 6, p. 652, doi. 10.1097/01.HS9.0000845912.50259.67

By:

Bazinet, A.;
Jabbour, E.;
Kantarjian, H.;
Chien, K.;
DiNardo, C.;
Ohanian, M.;
Daver, N.;
Kanagal‐Shamanna, R.;
Kadia, T.;
Takahashi, K.;
Masarova, L.;
Short, N.;
Alvarado, Y.;
Thompson, P.;
Montalban‐Bravo, G.;
Yilmaz, M.;
Ravandi, F.;
Konopleva, M.;
Andreeff, M.;
Kornblau, S.

Publication type:

Article

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA.

Published in:

HemaSphere, 2022, v. 6, p. 475, doi. 10.1097/01.HS9.0000845192.65192.c0

By:

Senapati, J.;
Ishizawa, J.;
Abbas, H. A.;
Loghavi, S.;
Borthakur, G.;
Issa, G. C.;
Dara, S. I.;
Pourebrahim, R.;
Daver, N.;
Jabbour, E. J.;
Kornblau, S. M.;
Pemmaraju, N.;
Garcia‐Manero, G.;
Ravandi, F.;
Muftuoglu, M.;
Khoury, J.;
DiNardo, C.;
Andreeff, M.

Publication type:

Article

P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA.

Published in:

HemaSphere, 2022, v. 6, p. 405, doi. 10.1097/01.HS9.0000844912.65235.a5

By:

Bazinet, A.;
Kadia, T.;
Short, N.;
Borthakur, G.;
Wang, S.;
Loghavi, S.;
Jorgensen, J.;
Patel, K.;
DiNardo, C.;
Daver, N.;
Alvarado, Y.;
Haddad, F.;
Pierce, S.;
Andreeff, M.;
Jabbour, E.;
Konopleva, M.;
Kantarjian, H.;
Ravandi, F.

Publication type:

Article

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3‐ITD MUTATED ACUTE MYELOID LEUKEMIA ‐ A PHASE I/II STUDY.

Published in:

HemaSphere, 2022, v. 6, p. 28, doi. 10.1097/01.HS9.0000843400.36721.1d

By:

Yilmaz, M.;
Muftuoglu, M.;
Kantarjian, H.;
DiNardo, C.;
Kadia, T.;
Borthakur, G.;
Pemmaraju, N.;
Short, N.;
Alvarado, Y.;
Maiti, A.;
Masarova, L.;
Montalban Bravo, G.;
Loghavi, S.;
Patel, K.;
Kornblau, S.;
Jabbour, E.;
Garcia‐Manero, G.;
Andreeff, M.;
Daver, N.

Publication type:

Article

GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer.

Published in:

Oncogene, 2015, v. 34, n. 23, p. 2958, doi. 10.1038/onc.2014.245

By:

Sarkar, T R;
Battula, V L;
Werden, S J;
Vijay, G V;
Ramirez-Peña, E Q;
Taube, J H;
Chang, J T;
Miura, N;
Porter, W;
Sphyris, N;
Andreeff, M;
Mani, S A

Publication type:

Article

Nachweis von minimaler Resterkrankung bei Patienten mit akuter myeloischer Leukämie und myelodysplastischem Syndrom in klinischer Remission mittels molekularer Zytogenetik.

Published in:

Journal of Laboratory Medicine / Laboratoriums Medizin, 1997, v. 21, n. 11, p. 613

By:

Engel, H.;
Goodacre, A.;
Keyhani, A.;
Jiang, S.;
Van, N. T.;
Kimmel, M.;
Sanchez-Williams, G.;
Andreeff, M.

Publication type:

Article

DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations.

Published in:

1991

By:

Tafuri, Agostino;
Meyers, Jane;
Lee, Burton J.;
Andreeff, Michael;
Tafuri, A;
Meyers, J;
Lee, B J;
Andreeff, M

Publication type:

journal article

Characterization of two newly established human cell lines from patients with large-cell anaplastic lung carcinoma.

Published in:

1982

By:

Anger, B.;
Oettgen, H. F.;
Old, L. J.;
Bockman, R.;
Andreeff, M.;
Erlandson, R.;
Saigo, P.;
Jhanwar, S.;
Kameya, T.;
Wright, W.;
Beattie, E. J.;
Beattie, E J Jr

Publication type:

journal article

Cell kinetics in acute leukemia: a critical reevaluation based on new data.

Published in:

1982

By:

Hiddemann, Wolfgang;
Büchner, Thomas;
Andreeff, Micheal;
Wörmann, Bernhard;
Melamed, Myron R.;
Clarkson, Bayard D.;
Hiddemann, W;
Büchner, T;
Andreeff, M;
Wörmann, B;
Melamed, M R;
Clarkson, B D

Publication type:

journal article

Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor.

Published in:

Oncogene, 2012, v. 31, n. 23, p. 2849, doi. 10.1038/onc.2011.462

By:

Sugihara, E;
Shimizu, T;
Kojima, K;
Onishi, N;
Kai, K;
Ishizawa, J;
Nagata, K;
Hashimoto, N;
Honda, H;
Kanno, M;
Miwa, M;
Okada, S;
Andreeff, M;
Saya, H

Publication type:

Article

The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.

Published in:

Oncogene, 2012, v. 31, n. 1, p. 68, doi. 10.1038/onc.2011.213

By:

Badgwell, D B;
Lu, Z;
Le, K;
Gao, F;
Yang, M;
Suh, G K;
Bao, J-J;
Das, P;
Andreeff, M;
Chen, W;
Yu, Y;
Ahmed, A A;
S-L Liao, W;
Bast, R C

Publication type:

Article

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.

Published in:

Cell Death & Differentiation, 2007, v. 14, n. 9, p. 1667, doi. 10.1038/sj.cdd.4402168

By:

Kuroda, J.;
Kimura, S.;
Strasser, A.;
Andreeff, M.;
O'Reilly, L. A.;
Ashihara, E.;
Kamitsuji, Y.;
Yokota, A.;
Kawata, E.;
Takeuchi, M.;
Tanaka, R.;
Tabe, Y.;
Taniwaki, M.;
Maekawa, T.

Publication type:

Article

Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1.

Published in:

Cell Death & Differentiation, 2007, v. 14, n. 8, p. 1443, doi. 10.1038/sj.cdd.4402139

By:

Tabe, Y.;
Jin, L.;
Contractor, R.;
Gold, D.;
Ruvolo, P.;
Radke, S.;
Xu, Y.;
Tsutusmi-Ishii, Y.;
Miyake, K.;
Miyake, N.;
Kondo, S.;
Ohsaka, A.;
Nagaoka, I.;
Andreeff, M.;
Konopleva, M.

Publication type:

Article

Differential Sensitivity of CD4+ and CD8+ T Lymphocytes to Phorbol Myristate Acetate upon Anti-CD3 Stimulation: Evidence for a Distinct Signaling Pathway.

Published in:

International Journal of Immunopathology & Pharmacology, 1991, v. 4, n. 1, p. 19, doi. 10.1177/039463209100400103

By:

Chouaib, S.;
Mahe, Yann;
Mechri, Salah;
Andreeff, M.;
Welte, K.

Publication type:

Article

Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML.

Published in:

Apoptosis, 2014, v. 19, n. 4, p. 698, doi. 10.1007/s10495-013-0954-z

By:

Mak, P.;
Mak, D.;
Mu, H.;
Shi, Y.;
Ruvolo, P.;
Ruvolo, V.;
Jacamo, R.;
Burks, J.;
Wei, W.;
Huang, X.;
Kornblau, S.;
Andreeff, M.;
Carter, B.

Publication type:

Article

Apoptosis effector mechanisms: A requiem performed in different keys.

Published in:

Apoptosis, 2006, v. 11, n. 6, p. 889, doi. 10.1007/s10495-006-6712-8

By:

Hail Jr., N.;
Carter, B. Z.;
Konopleva, M.;
Andreeff, M.

Publication type:

Article

Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.

Published in:

1995

By:

Preti, H. Alejandro;
Huh, Yang O.;
O'Brien, Susan M.;
Andreeff, Michael;
Pierce, Sherry T.;
Keating, Michael;
Kantarjian, Hagop M.;
Preti, H A;
Huh, Y O;
O'Brien, S M;
Andreeff, M;
Pierce, S T;
Keating, M;
Kantarjian, H M

Publication type:

journal article

Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.

Published in:

Journal of Clinical Apheresis, 2001, v. 16, n. 2, p. 82, doi. 10.1002/jca.1017

By:

Körbling, M.;
Giralt, S.;
Khouri, I.;
Mirza, N.;
Donato, M.;
Anderlini, P.;
Fischer, H.;
Andreeff, M.;
McMannis, J.;
Champlin, R.

Publication type:

Article

Childhood CML in blastic stage: An analysis of cell markers and cell kinetics.

Published in:

American Journal of Hematology, 1980, v. 9, n. 3, p. 337, doi. 10.1002/ajh.2830090313

By:

Beck, J. D.;
Andreeff, M.;
Mertelsmann, R.;
Haghbin, M.;
Tan, C.;
Miller, D. R.;
Good, R. A.;
Gupta, S.

Publication type:

Article

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.

Published in:

Leukemia (08876924), 2014, v. 28, n. 7, p. 1543, doi. 10.1038/leu.2014.54

By:

Ravandi, F;
Arana Yi, C;
Cortes, J E;
Levis, M;
Faderl, S;
Garcia-Manero, G;
Jabbour, E;
Konopleva, M;
O'Brien, S;
Estrov, Z;
Borthakur, G;
Thomas, D;
Pierce, S;
Brandt, M;
Pratz, K;
Luthra, R;
Andreeff, M;
Kantarjian, H

Publication type:

Article

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.

Published in:

Leukemia (08876924), 2013, v. 27, n. 6, p. 1358, doi. 10.1038/leu.2012.366

By:

Zhou, L;
Ruvolo, V R;
McQueen, T;
Chen, W;
Samudio, I J;
Conneely, O;
Konopleva, M;
Andreeff, M

Publication type:

Article

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.

Published in:

Leukemia (08876924), 2012, v. 26, n. 5, p. 883, doi. 10.1038/leu.2011.291

By:

Tabe, Y;
Jin, L;
Iwabuchi, K;
Wang, R-Y;
Ichikawa, N;
Miida, T;
Cortes, J;
Andreeff, M;
Konopleva, M

Publication type:

Article

Activation of apoptosis signaling eliminates CD34<sup>+</sup> progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.

Published in:

Leukemia (08876924), 2012, v. 26, n. 4, p. 788, doi. 10.1038/leu.2011.285

By:

Mak, D H;
Wang, R-Y;
Schober, W D;
Konopleva, M;
Cortes, J;
Kantarjian, H;
Andreeff, M;
Carter, B Z

Publication type:

Article

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Published in:

Leukemia (08876924), 2012, v. 26, n. 4, p. 778, doi. 10.1038/leu.2011.287

By:

Konopleva, M;
Milella, M;
Ruvolo, P;
Watts, J C;
Ricciardi, M R;
Korchin, B;
McQueen, T;
Bornmann, W;
Tsao, T;
Bergamo, P;
Mak, D H;
Chen, W;
McCubrey, J;
Tafuri, A;
Andreeff, M

Publication type:

Article

MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML.

Published in:

Leukemia (08876924), 2012, v. 26, n. 3, p. 443, doi. 10.1038/leu.2011.246

By:

Carter, B Z;
Mak, D H;
Shi, Y;
Fidler, J M;
Chen, R;
Ling, X;
Plunkett, W;
Andreeff, M

Publication type:

Article

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients.

Published in:

2011

By:

Ruvolo, P P;
Qui, Y H;
Coombes, K R;
Zhang, N;
Ruvolo, V R;
Borthakur, G;
Konopleva, M;
Andreeff, M;
Kornblau, S M

Publication type:

journal article

Physiological hypoxia promotes lipid raft and PI3K-dependent activation of MAPK 42/44 in leukemia cells.

Published in:

2010

By:

Fiegl, M.;
Samudio, I.;
Mnjoyan, Z.;
Korchin, B.;
Fritsche, H.;
Andreeff, M.

Publication type:

Letter

Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.

Published in:

2010

By:

Kojima, K.;
Konopleva, M.;
Tsao, T.;
Andreeff, M.;
Ishida, H.;
Shiotsu, Y.;
Jin, L.;
Tabe, Y.;
Nakakuma, H.

Publication type:

journal article

Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells.

Published in:

2009

By:

Carter, B. Z.;
Mak, D. H.;
Woessner, R.;
Gross, S.;
Schober, W. D.;
Estrov, Z.;
Kantarjian, H.;
Andreeff, M.

Publication type:

journal article

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.

Published in:

2009

By:

Drakos, E.;
Atsaves, V.;
Li, J.;
Leventaki, V.;
Andreeff, M.;
Medeiros, L. J.;
Rassidakis, G. Z.

Publication type:

journal article

HOX expression patterns identify a common signature for favorable AML.

Published in:

2008

By:

Andreeff, M.;
Ruvolo, V.;
Gadgil, S.;
Zeng, C.;
Coombes, K.;
Chen, W.;
Kornblau, S.;
Barón, A. E.;
Drabkin, H. A.;
Barón, A E

Publication type:

journal article

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.

Published in:

2008

By:

Kojima, K.;
Shimanuki, M.;
Shikami, M.;
Samudio, I. J.;
Ruvolo, V.;
Corn, P.;
Hanaoka, N.;
Konopleva, M.;
Andreeff, M.;
Nakakuma, H.

Publication type:

journal article

Synthetic triterpenoids have cytotoxicity in pediatric acute lymphoblastic leukemia cell lines but cytotoxicity is independent of induced ceramide increase in MOLT-4 cells.

Published in:

2008

By:

Kong, G.;
Wang, D.;
Wang, H.;
Wu, J.;
Bielawski, J.;
Konopleva, M.;
Andreeff, M.;
Ruvolo, P. P.;
Maurer, B. J.

Publication type:

Letter

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications.

Published in:

2008

By:

Fabbri, M.;
Garzon, R.;
Andreeff, M.;
Kantarjian, H. M.;
Garcia-Manero, G.;
Calin, G. A.

Publication type:

journal article

Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.

Published in:

2008

By:

Zhang, W.;
Konopleva, M.;
Ruvolo, V. R.;
McQueen, T.;
Evans, R. L.;
Bornmann, W. G.;
McCubrey, J.;
Cortes, J.;
Andreeff, M.

Publication type:

journal article

Bcl2 phosphorylation and active PKC α are associated with poor survival in AML.

Published in:

2006

By:

Kurinna, S;
Konopleva, M;
Palla, S L;
Chen, W;
Kornblau, S;
Contractor, R;
Deng, X;
May, W S;
Andreeff, M;
Ruvolo, P P

Publication type:

Letter

Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.

Published in:

Leukemia (08876924), 2006, v. 20, n. 4, p. 610, doi. 10.1038/sj.leu.2404140

By:

Pelicano, H.;
Carew, J. S.;
McQueen, T. J.;
Andreeff, M.;
Plunkett, W.;
Keating, M. J.;
Huang, P.

Publication type:

Article

Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.

Published in:

Leukemia (08876924), 2005, v. 19, n. 11, p. 1977, doi. 10.1038/sj.leu.2403929

By:

Zhang, W.;
McQueen, T.;
Schober, W.;
Rassidakis, G.;
Andreeff, M.;
Konopleva, M.

Publication type:

Article

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.

Published in:

Leukemia (08876924), 2005, v. 19, n. 9, p. 1543, doi. 10.1038/sj.leu.2403859

By:

Ricciardi, M. R.;
McQueen, T.;
Chism, D.;
Milella, M.;
Estey, E.;
Kaldjian, E.;
Sebolt-Leopold, J.;
Konopleva, M.;
Andreeff, M.

Publication type:

Article

The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.

Published in:

2005

By:

Konopleva, M.;
Contractor, R.;
Kurinna, S. M.;
Chen, W.;
Andreeff, M.;
Ruvolo, P. P.

Publication type:

journal article

PKC a mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation.

Published in:

Leukemia (08876924), 2004, v. 18, n. 3, p. 505, doi. 10.1038/sj.leu.2403275

By:

Jiffar, T.;
Kurinna, S.;
Suck, G.;
Carlson-Bremer, D.;
Ricciardi, M.R.;
Konopleva, M.;
Andreeff, M.;
Ruvolo, P.P.

Publication type:

Article

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.

Published in:

2004

By:

Zhao, S.;
Konopleva, M.;
Cabreira-Hansen, M.;
Xie, Z.;
Hu, W.;
Milella, M.;
Estrov, Z.;
Mills, G.B.;
Andreeff, M.

Publication type:

journal article

Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL.

Published in:

2003

By:

Suh, W-S.;
Kim, Y. S.;
Schimmer, A. D.;
Kitada, S.;
Minden, M.;
Andreeff, M.;
Suh, N.;
Sporn, M.;
Reed, J. C.

Publication type:

journal article

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

Published in:

Leukemia (08876924), 2003, v. 17, n. 11, p. 2081, doi. 10.1038/sj.leu.2403113

By:

Carter, B. Z.;
Milella, M.;
Tsao, T.;
McQueen, T.;
Schober, W. D.;
Hu, W.;
Dean, N. M.;
Steelman, L.;
McCubrey, J. A.;
Andreeff, M.

Publication type:

Article